Most people who develop diabetes after starting statins were already very close to having diabetes before they began treatment—statins don’t cause diabetes in healthy people, but they push those on the edge over the diagnostic line.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of individual participant data across multiple RCTs could confirm whether the proportion of statin-attributable diabetes cases concentrated in the top glycaemic quartile is consistent across diverse populations.
A pooled analysis of individual-level data from 30+ RCTs of statins, stratifying all participants by baseline HbA1c quartiles, calculating the proportion of new-onset diabetes cases occurring in each quartile, and adjusting for age, BMI, and trial design.
An RCT could confirm that statin-induced diabetes cases are disproportionately concentrated in individuals with baseline HbA1c 5.7–6.4% compared to those below 5.5%.
A double-blind RCT of 5,000 adults aged 50–70 with baseline HbA1c 5.5–6.4% randomized to high-intensity statin or placebo, with diabetes diagnosed by HbA1c ≥6.5% at 12-month intervals, stratifying new cases by baseline quartile.
Could determine whether individuals with baseline HbA1c in the top quartile have a higher absolute risk of developing diabetes when exposed to statins compared to those in lower quartiles.
A prospective cohort of 20,000 adults aged 45–75 without diabetes, with baseline HbA1c measured, followed for 8 years, tracking statin initiation and diabetes diagnosis, comparing incidence rates across baseline quartiles.
Could estimate the odds of being in the top glycaemic quartile among statin users who developed diabetes versus those who did not.
A case-control study of 1,500 statin users diagnosed with diabetes and 3,000 matched statin users without diabetes, comparing baseline HbA1c levels and quartile distribution prior to diagnosis.
Could show the proportion of statin users with diabetes who had high baseline HbA1c, but cannot determine if statins caused the diagnosis.
A cross-sectional survey of 10,000 statin users with diabetes, recording their most recent pre-statin HbA1c value and categorizing them into quartiles.